The technologies being tested in this larger clinical trial has two components: an optical wand and a multispectral colposcope (MDC).
The optical wand makes use of fluorescence and reflectance spectroscopy; a light is shone on the cervix and the wand reports what it sees to a computer in the examining room. Since cancer cells interact with light differently than healthy cells, a computer can detect regions of abnormality.
The MDC is based on a conventional colposcope, a tool already in widespread clinical use. However, the MDC also has the ability to produce fluorescence and polarized reflectance images of the entire cervix. Computer analysis of these images can detect abnormalities on the cervix, defining both their location and their shape.
In this trial, we will analyze data from the optical wand and the MDC both separately and together. Combining these data may lead to more effective diagnosis of cervical abnormalities.
“These new optical devices require less training and fewer visual recognition skills than standard colposcopy. They narrow the reporting time and may reduce the false positive rates by as much as 40%.”

- Dr. Michele Follen
One benefit of the new devices being tested is that, unlike standard screening methods, test results could be immediately available. This would remove the need for invasive biopsies or 2-week follow-up appointments to confirm the presence of diseased cells.

The BC Cancer Agency is looking for women willing to participate in this clinical trial.
The Digital Colposcopy Trial

Testing a tool for cervical cancer screening in British Columbia